Citations

Showing 10 of 108104 citations.

TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive bre
Connolly, Roisín M. , Leal, Jeffrey P. , Sólnes, Lilja B. , Carpenter, Ashley , Gaffney, Katy, Liu, Minetta C. , Rimawi, Mothaffar F. , Specht, Jennifer M. , Storniolo, Anna Maria , Valero, Vicente , Camp, Melissa , Cimino‐Mathews, Ashley , Rimawi, Mothaffar , Specht, Jennifer , Huang, Chiung‐Yu , Gaffney, Katy, Abramson, Vandana G. , Carey, Lisa A. , Vaklavas, Christos , Miller, Robert S. , Wolff, Antonio C. , Wahl, Richard L. , Stearns, Vered

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 511-511

10.1200/jco.2018.36.15_suppl.511 Get It

TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
Konstantinopoulos, Panagiotis A. , Waggoner, Steven , Vidal, Gregory A. , Mita, Monica , Holloway, Robert W. , Le, Linda Van, Sachdev, Jasgit C. , Chapman‐Davis, Eloise , Colón‐Otero, Gerardo , Penson, Richard T. , Matulonis, Ursula A. , Kim, Young B., Dezube, Bruce J., Wang, Jing Y., Buerstatte, Nathan, Arora, Sujata, Münster, Pamela N. , Munster, Pamela , Konstantinopoulos, Panagiotis A , Fleming, Gini F. , Moore, Kathleen N. , Swisher, Elizabeth M.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 106-106

10.1200/jco.2018.36.15_suppl.106 Get It

A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
Henderson, Meredith C. , Silver, Michael, Tran, Quynh Hoa, Letsios, Elias, Mulpuri, Rao, Reese, David E., Lourenço, Ana P. , Anderson, Karen S. , Alpers, Josie , Costantini, Carrie , Rohatgi, Nitin, Ali, Haythem , Baker, Karen, Northfelt, Donald W. , Ghosh, Karthik, Grobmyer, Stephen R. , Polen, Winnie, Wolf, Judith K., Ali, Haythem , Tran, Quynh, Letsios, Elias E., LaBaer, Joshua , Baker, Karen

Mayo Clinic

Clinical Cancer Research | September 5, 2018 | Volume: 25 | Issue: 1 | Pages: 142-149

10.1158/1078-0432.ccr-18-0843 | PMID 30185421 Get It

Abstract Purpose: With improvements in breast cancer imaging, there has been a corresponding increase in false-positives and avoidable biopsies. There is a need to better differentiate when a breast biopsy is warranted and determine appropriate follow-up. This study describes the design and clinical performance of a combinatorial proteomic biomarker assay (CPBA), Videssa Breast, in women over age 50 years. Experimental Design: A BI-RADS 3, 4, or 5 assessment was required for clinical trial enrollment. Serum was collected prior to breast biopsy and subjects were followed for 6–12 months and clinically relevant outcomes were recorded. Samples were split into training (70%) and validation (30%) cohorts with an approximate 1:4 case:control ratio in both arms. Results: A CPBA that combines biomarker data with patient clinical data was developed using a training cohort (469 women, cancer incidence: 18.5%), resulting in 94% sensitivity and 97% negative predictive value (NPV). Independent validation of the final algorithm in 194 subjects (breast cancer incidence: 19.6%) demonstrated a sensitivity of 95% and a NPV of 97%. When combined with previously published data for women under age 50, Videssa Breast achieves a comprehensive 93% sensitivity and 98% NPV in a population of women ages 25–75. Had Videssa Breast results been incorporated into the clinical workflow, approximately 45% of biopsies might have been avoided. Conclusions: Videssa Breast combines serum biomarkers with clinical patient characteristics to provide clinicians with additional information for patients with indeterminate breast imaging results, potentially reducing false-positive breast biopsies.
TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.
Ravi, Vinod , Chawla, Sant P. , Attia, Steven , Riedel, Richard F. , Thornton, Katherine A., Mallick, Atrayee Basu , Liu, Lingyun , Alvarez, Delia, Theuer, Charles P. , Tap, William D. , Jones, Robin L. , Maki, Robert G. , Maki, Robert G , Riedel, Richard F , Jones, Robin L , Brohl, Andrew S. , Liebner, David A. , Mehta, Cyrus R. , Robinson, Steven I. , Penel, Nicolas , Stacchiotti, Silvia

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS11590-TPS11590

10.1200/jco.2018.36.15_suppl.tps11590 Get It

Subgroup analysis of elderly patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial.
Younger, Eugenie , Pápai, Zsuzsanna , Tine, Brian Andrew Van, Attia, Steven , Lu, Yao , Schöffski, Patrick , Tap, William D. , Jones, Robin L. , Jones, Robin L , Ballman, Karla V. , Reinke, Denise K.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11575-11575

10.1200/jco.2018.36.15_suppl.11575 Get It

A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
Agulnik, Mark , Mohindra, Nisha , Attia, Steven , Rademaker, Alfred , Abbinanti, Susan, Cehic, Rasima, Humphreys, Catherine , Okuno, Scott H. , Tine, Brian Andrew Van, Milhem, Mohammed , Robinson, Steven I. , Humphreys, Catherine, Prudner, Bethany Cheree

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11550-11550

10.1200/jco.2018.36.15_suppl.11550 Get It

Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.
Villalobos, Víctor M. , Tine, Brian Andrew Van, Dickson, Mark A. , Cronier, Damien M., Attia, Steven , Redondo, Andrés , Schwartz, Gary K. , Chmielowski, Bartosz , Peterson, Patrick M. , Wright, Jennifer

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11542-11542

10.1200/jco.2018.36.15_suppl.11542 Get It

Quantitative assessment of learning behaviors for oncology providers.
Wood, Marie , Polansky, Maura , Baer, Allyson, Grupe, Anne, Wang, Cathy, Horn, Leora , George, Thomas J. , Manochakian, Rami , Shyr, Yu

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11004-11004

10.1200/jco.2018.36.15_suppl.11004 Get It

ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors.
Malempati, Suman , Liu, Xiaowei , Fox, Elizabeth , Weigel, Brenda J. , Chang, Bill H , Reid, Joel M. , Minard, Charles G. , Keller, Charles

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 10556-10556

10.1200/jco.2018.36.15_suppl.10556 Get It

Rose geranium in sesame oil nasal spray: A potential treatment for nasal vestibulitis?
Smith, Deanne, Zahrieh, David , Loprinzi, Charles L. , Cathcart-Rake, Elizabeth , Goyal, Gaurav

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e22166-e22166

10.1200/jco.2018.36.15_suppl.e22166 Get It